The Growing Federal Crackdown on Diversion Schemes: What Healthcare Providers Need to Know

In December 2024, federal prosecutors secured prison sentences for two Miami men involved in a large-scale scheme that diverted HIV medications and cost Medicare Part D nearly $28 million. While many providers see such cases as remote “pharmacy fraud,” this prosecution is a direct warning to clinics, prescribers, and practice owners across the country. The Department of Justice (DOJ) is intensifying oversight not only of criminal enterprises but also of clinics, prescribers, and medical practices whose internal controls—or lack of them—allow exploitation by third parties.

This analytical review examines what happened in the Miami case, why the federal government is prioritizing drug-diversion crimes, and what healthcare providers should proactively do to protect their practices from risk.

What Happened in the Miami Case

According to court filings, Alexander Lombardi and Anthony Antonucci operated a network of shell companies designed to purchase and resell diverted prescription medications, including antiretroviral drugs used to treat HIV. These medications were originally acquired through illicit channels—stolen, fraudulently obtained, or purchased from vulnerable individuals—and then re-introduced into the supply chain with falsified documentation.

The scheme relied on:

• Falsified pedigrees and invoices to make diverted drugs appear legitimate
• Sham wholesale distributors that existed only on paper
• Manipulated supply chain paperwork to obscure the true source of the drugs
• Sales to licensed pharmacies, who were deceived and believed they were purchasing legitimate inventory

These falsified records helped the conspirators exploit Medicare Part D, causing nearly $28 million in fraudulent claims by pharmacies that unwittingly dispensed diverted medications.

Lombardi and Antonucci each received nearly five years in federal prison, reflecting the severity with which DOJ now views diversion-related conduct.

Why the DOJ Is Intensifying Its Focus

Federal authorities have repeatedly emphasized that drug-diversion schemes threaten patient safety, undermine trust in pharmacies, and inflate the cost of Medicare and Medicaid.

Several overlapping enforcement trends explain the increased pressure:

1. Heightened Medicare Part D Oversight

Drug spending under Part D continues to grow, and diversion schemes disproportionately impact high-cost specialty medications, such as antiretrovirals. DOJ and HHS-OIG have moved these cases into their top priority categories, especially when vulnerable populations—such as patients with HIV—may receive ineffective or adulterated medications.

2. More Sophisticated Fraud Tactics

Diversion networks increasingly use:

• Fake wholesale distributors
• Manipulated or stolen provider identities
• Shell companies with complex ownership structures
• Cash purchases from patients struggling with addiction or economic hardship

When paperwork looks legitimate but patient outcomes deteriorate, providers risk unknowingly becoming part of a fraudulent supply chain.

3. Emphasis on Upstream Responsibility

The DOJ’s objective is clear: target the entire supply chain, not only wholesalers and illicit brokers. Clinics, prescribers, pharmacies, and even billing organizations may face scrutiny if their systems fail to detect red flags.

How This Case Connects to Private Practice Risk

Many providers assume they are insulated from diversion schemes because they do not handle large medication inventories. However, the Miami case illustrates several risks highly relevant to outpatient practices:

1. Prescription Patterns Can Trigger Investigations

If a provider’s prescribing activity appears inconsistent with clinical norms—either too high or too concentrated in specific therapeutic categories—this can draw attention to potential diversion.

Providers may not be complicit, but they may still be investigated.

2. Third-Party Actors Can Exploit Weak Controls

Fraudsters frequently target:

• Clinics with poor identity-verification procedures
• Prescribers who do not monitor refill histories
• Medical assistants or front-desk staff who lack training to spot unusual behaviors

Even if a practice is not involved, its data, NPI numbers, or prescriptions can be leveraged for fraudulent purposes.

3. Pharmacy Relationships Matter

Many diversion schemes rely on placing illegitimate medications into the legitimate supply chain. Pharmacies—especially small or independent ones—may unintentionally distribute diverted drugs. Providers who work with pharmacies later implicated in diversion can find themselves pulled into compliance reviews.

Key Warning Signs Providers Should Watch For

To avoid entanglement in diversion-related investigations, practices should remain alert to the following high-risk indicators:

Red Flags in Prescription Activity

• Patients frequently requesting early refills
• Multiple patients connected to the same location or caseworker using identical medication regimens
• Prescriptions inconsistent with the provider’s clinical specialty

Patient Behavioral Indicators

• Patients offering cash for prescriptions
• Reports of lost or stolen medications
• Requests to change pharmacies frequently without clear justification

Internal Staff Issues

• Staff members who bypass proper prescription-tracking workflows
• Unauthorized access to the EHR or prescribing system
• Willingness to bypass ID checks or clinical documentation

External Pressures

• Pharmacy requests for unusually large or repetitive volumes
• Third parties offering “support services” that include patient recruitment
• Brokers or case managers bringing multiple patients to the clinic

What Providers Should Do to Protect Their Practices

Given recent DOJ actions, the following steps are no longer optional—they are essential for operational and legal protection.

1. Strengthen Prescription Monitoring

• Use state PDMP (Prescription Drug Monitoring Program) checks consistently.
• Implement internal logs for high-risk drug classes.
• Require secondary review for unusual refill patterns.

2. Update Policies and Train Staff

Ensure your practice has:

• Clear prescription-related policies
• Procedures for verifying patient identity
• Training on recognizing diversion behaviors
• Documented workflows for prior authorizations and refills

Training should be repeated annually.

3. Audit Your EHR and Billing Systems

• Review prescribing patterns quarterly
• Ensure all NPIs used under the practice belong to active, authorized providers
• Confirm that no external party has unauthorized system access

4. Evaluate Pharmacy Partners

While providers cannot dictate where patients fill prescriptions, they can monitor for pharmacy-related red flags:

• Unusually high volume of calls from a single pharmacy
• Requests for large quantities not clinically justified
• Patterns of dispensing anomalies reported by insurers

5. Build a Relationship With Compliance Experts

A billing compliance department or external auditor can flag issues early. Providers should also consult legal counsel familiar with Medicare fraud statutes (including the False Claims Act).

The Miami diversion case is not an isolated event but part of a broad federal strategy to dismantle schemes that exploit Medicare and endanger patients. Providers who implement stronger controls, train their staff, and monitor prescription activity will significantly reduce risk. In the current enforcement climate, vigilance is not only prudent—it is mandatory.

Sources

1. https://www.justice.gov/usao-sdfl/pr/two-miami-men-sentenced-nearly-five-years-prison-28-million-scheme-involving-diverted
2. https://oig.hhs.gov/fraud/enforcement/two-miami-men-sentenced-to-nearly-five-years-in-prison-for-28-million-scheme-involving-diverted-pharmaceuticals/
3. https://townhall.com/tipsheet/scott-mcclallen/2025/12/07/two-miami-men-get-57-months-for-nationwide-sale-of-diverted-hiv-and-cancer-drugs-n2667493
4. https://www.caribbeannationalweekly.com/news/local-news/two-miami-men-sentenced-in-28m-scheme-involving-diverted-hiv-and-cancer-drugs/
5. https://en.cibercuba.com/noticias/2025-12-09-u1-e129488-s27061-nid316366-condenan-polemico-empresario-cubano-boris-arencibia
6. https://www.justice.gov/usao-sdfl/pr/owner-pharmaceutical-company-pleads-guilty-unlawful-distribution-60-million-diverted
7. https://www.justice.gov/usao-sdfl/pr/owners-and-ceo-wholesale-pharmaceutical-company-convicted-distributing-more-92-million
8. https://wsvn.com/news/local/broward/maryland-brothers-convicted-in-south-florida-black-market-hiv-drug-scheme-feds-say/?utm_source=chatgpt.com
9. https://www.justice.gov/usao-sdfl/pr/south-florida-resident-sentenced-elaborate-prescription-medication-diversion-scheme